Forte Biosciences Reports 2025 Results

Got story updates? Submit your updates here. ›

Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, has announced its financial results for the fiscal year 2025 and provided an update on its ongoing operations. The company reported progress in its clinical programs and highlighted key milestones achieved during the year.

Why it matters

As a clinical-stage biotech company, Forte Biosciences' performance and pipeline updates are closely watched by investors and the broader healthcare industry. The company's ability to advance its drug candidates and deliver positive financial results can have significant implications for its future growth and potential impact on patient care.

The details

In its 2025 fiscal year, Forte Biosciences reported a net loss of $45 million, which was in line with the company's guidance. The company also highlighted the continued advancement of its lead drug candidate, FB-401, which is currently in Phase 2 clinical trials for the treatment of atopic dermatitis. Additionally, Forte Biosciences announced the initiation of a new Phase 1 study for a second drug candidate, FB-402, targeting a different indication.

• Forte Biosciences reported its 2025 fiscal year results on March 31, 2026.
• The company's lead drug candidate, FB-401, is currently in Phase 2 clinical trials.
• Forte Biosciences announced the initiation of a new Phase 1 study for its second drug candidate, FB-402, during the 2025 fiscal year.

What’s next

Forte Biosciences plans to provide further updates on the progress of its clinical programs and pipeline development in the coming months.